Thyroid Dysfunction After Immune Checkpoint Inhibition May Be Underreported in Non-Small Cell Lung Cancer
Most patients studied did not have thyroid labs obtained after immune checkpoint inhibitor treatment.
Non-Small Cell Lung Cancer
Tecentriq Approved as Adjuvant Treatment for Early NSCLC
The approval was based on data from the phase 3 IMpower010 study.
Poziotinib Shows Promise in HER2 Exon 20-Mutant Non-Small Cell Lung Cancer
The confirmed response rate was 27%, and the median progression-free survival was 5.5 months.
eNose Identifies Early Responders to Immunotherapy Among Non-Small Cell Lung Cancer Patients
The technology could save patients from ineffective treatment, according to researchers.
Pretreatment ctDNA Predicts Survival in Non-Small Cell Lung Cancer
PD-L1 expression and tumor mutational burden were not associated with survival.
Adding Immunotherapy to Chemo Improves Survival in Metastatic Non-Small Cell Lung Cancer
The combinations conferred benefits in nonsquamous non-small cell lung cancer only.
Sugemalimab Deemed Effective as Consolidation for Stage III Non-Small Cell Lung Cancer
Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
Brigatinib Continues to Best Crizotinib in ALK+ Non-Small Cell Lung Cancer
There was an improvement in progression-free survival despite crossover.
Type of Surgery and Surgical Pathway Tied to Risk of Perioperative COVID-19 in Non-Small Cell Lung Cancer
Perioperative COVID-19 was associated with a 30-day mortality rate of 26%.
- Loading...
Loading...
Next post in IASLC 2021
Loading... 
Loading...